605369.SS
Zhejiang Gongdong Medical Technology Co.,Ltd. [605369.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
605369.SS Stock Summary
Top 10 Correlated Stocks
605369.SS
In the News
605369.SS Financial details
Company Rating
Buy
Market Cap
5.47B
Income
105.85M
Revenue
1B
Book val./share
14.4
Cash/share
4.44
Dividend
0.8
Dividend %
1.64%
Employees
1.78K
Optionable
No
Shortable
Yes
Earnings
27 Oct 2023
P/E
50.52
Forward P/E
-
PEG
-7.67
P/S
5.48
P/B
3.31
P/C
9.71
P/FCF
122.22
Quick Ratio
3.14
Current Ratio
3.63
Debt / Equity
-0.02
LT Debt / Equity
0
-
-
EPS (TTM)
0.95
EPS next Y
-
EPS next Q
-
EPS this Y
4.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
23.57%
Revenue last 5Y
24.93%
Revenue Q/Q
9.68%
EPS Q/Q
-17.24%
-
-
-
-
SMA20
-4.17%
SMA50
2.22%
SMA100
-19.3%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
7%
ROC
0.07%
Gross Margin
32%
Oper. Margin
12%
Profit Margin
11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
34.08-69.67
52W High
-37.49%
52W Low
+26.85%
RSI
41
Rel Volume
1.47
Avg Volume
555.81K
Volume
816.78K
Perf Week
-7.51%
Perf Month
-4.85%
Perf Quarter
-16.53%
Perf Half Y
-21.32%
-
-
-
-
Beta
0.527
-
-
Volatility
2.01%, 1.61%
Prev Close
-2.42%
Price
43.13
Change
-3.4%
605369.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.76 | 4.94 | 7.41 | 10.66 | 13.11 | |
| Net income per share | 1.01 | 1.01 | 2.02 | 2.78 | 2.91 | |
| Operating cash flow per share | 1.22 | 1.09 | 2.16 | 3.33 | 2.52 | |
| Free cash flow per share | 0.79 | 0.18 | 1.19 | 0.87 | 0.99 | |
| Cash per share | 2.23 | 1.03 | 7.27 | 7.22 | 7.17 | |
| Book value per share | 4.08 | 3.62 | 10.79 | 12.39 | 14.21 | |
| Tangible book value per share | 3.6 | 2.87 | 10.05 | 11.67 | 13.5 | |
| Share holders equity per share | 4.08 | 3.62 | 10.79 | 12.39 | 14.21 | |
| Interest debt per share | 0.48 | -0.17 | -0.27 | 0.01 | 0 | |
| Market cap | 2.73B | 3.65B | 4.62B | 16.05B | 11.83B | |
| Enterprise value | 2.58B | 3.53B | 3.85B | 15.33B | 11.08B | |
| P/E ratio | 32.1 | 32.1 | 20.45 | 51.6 | 36.29 | |
| Price to sales ratio | 5.65 | 6.59 | 5.57 | 13.44 | 8.06 | |
| POCF ratio | 26.62 | 29.81 | 19.08 | 43.03 | 41.85 | |
| PFCF ratio | 40.96 | 182 | 34.58 | 164.72 | 107.02 | |
| P/B Ratio | 7.98 | 9 | 3.82 | 11.56 | 7.43 | |
| PTB ratio | 7.98 | 9 | 3.82 | 11.56 | 7.43 | |
| EV to sales | 5.35 | 6.39 | 4.64 | 12.84 | 7.54 | |
| Enterprise value over EBITDA | 22.88 | 23.42 | 13.49 | 40.11 | 26.26 | |
| EV to operating cash flow | 25.19 | 28.87 | 15.88 | 41.1 | 39.19 | |
| EV to free cash flow | 38.76 | 176.24 | 28.79 | 157.36 | 100.21 | |
| Earnings yield | 0.03 | 0.03 | 0.05 | 0.02 | 0.03 | |
| Free cash flow yield | 0.02 | 0.01 | 0.03 | 0.01 | 0.01 | |
| Debt to equity | 0.12 | -0.05 | -0.03 | 0 | 0 | |
| Debt to assets | 0.09 | -0.04 | -0.02 | 0 | 0 | |
| Net debt to EBITDA | -1.3 | -0.76 | -2.71 | -1.88 | -1.78 | |
| Current ratio | 2.7 | 2.21 | 6.41 | 3.89 | 4.31 | |
| Interest coverage | 347.77 | 199.44 | 1.4K | 12.61K | 10.34K | |
| Income quality | 1.21 | 1.08 | 1.07 | 1.2 | 0.87 | |
| Dividend Yield | 0 | 0.01 | 0 | 0.01 | 0.01 | |
| Payout ratio | 0 | 0.45 | 0 | 0.46 | 0.48 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | |
| Intangibles to total assets | 0.09 | 0.16 | 0.06 | 0.05 | 0.04 | |
| Capex to operating cash flow | -0.35 | -0.84 | -0.45 | -0.74 | -0.61 | |
| Capex to revenue | -0.07 | -0.18 | -0.13 | -0.23 | -0.12 | |
| Capex to depreciation | -2.8 | -6.23 | -5.74 | -12.64 | -4.18 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.01 | |
| Graham number | 9.65 | 9.09 | 22.12 | 27.83 | 30.5 | |
| ROIC | 0.22 | 0.3 | 0.19 | 0.22 | 0.21 | |
| Return on tangible assets | 0.2 | 0.25 | 0.17 | 0.19 | 0.18 | |
| Graham Net | 1.91 | 0.85 | 7.19 | 6.41 | 6.97 | |
| Working capital | 205.91M | 154.3M | 884.05M | 840.41M | 870.7M | |
| Tangible asset value | 301.22M | 320.92M | 1.13B | 1.31B | 1.51B | |
| Net current asset value | 204.22M | 151.48M | 879.64M | 829.75M | 858.29M | |
| Invested capital | 0.12 | -0.05 | -0.03 | 0 | 0 | |
| Average receivables | 96.5M | 111.69M | 142.92M | 186.03M | 231.1M | |
| Average payables | 39.38M | 63.16M | 75.85M | 106.81M | 145.55M | |
| Average inventory | 37.2M | 39.71M | 55.24M | 90.83M | 117.75M | |
| Days sales outstanding | 79.07 | 78.44 | 73.47 | 62.67 | 63.91 | |
| Days payables outstanding | 57.2 | 96.88 | 61.11 | 78.82 | 60.63 | |
| Days of inventory on hand | 46.13 | 51.47 | 58.51 | 62.91 | 49.69 | |
| Receivables turnover | 4.62 | 4.65 | 4.97 | 5.82 | 5.71 | |
| Payables turnover | 6.38 | 3.77 | 5.97 | 4.63 | 6.02 | |
| Inventory turnover | 7.91 | 7.09 | 6.24 | 5.8 | 7.35 | |
| ROE | 0.25 | 0.28 | 0.19 | 0.22 | 0.2 | |
| Capex per share | -0.43 | -0.91 | -0.97 | -2.46 | -1.54 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.42 | 2.58 | 2.02 | 2.07 | 2.27 | |
| Net income per share | 0.88 | 0.16 | 0.26 | 0.29 | 0.24 | |
| Operating cash flow per share | 0.88 | 0.16 | 0.26 | 0.37 | 0.31 | |
| Free cash flow per share | 0.48 | 0.02 | -0.06 | 0.22 | 0.22 | |
| Cash per share | 6.69 | 7.16 | 4.22 | 4.22 | 4.44 | |
| Book value per share | 14.12 | 14.19 | 14.43 | 14.59 | 14.4 | |
| Tangible book value per share | 13.41 | 13.48 | 11.92 | 11.82 | 11.67 | |
| Share holders equity per share | 14.12 | 14.19 | 14.43 | 14.59 | 14.4 | |
| Interest debt per share | 0.36 | 0.01 | -0.23 | 0.17 | -0.3 | |
| Market cap | 12.44B | 11.85B | 7.8B | 6.29B | 6.25B | |
| Enterprise value | 11.72B | 11.1B | 7.32B | 5.85B | 5.75B | |
| P/E ratio | 31.76 | 168.38 | 67.42 | 49.08 | 57.21 | |
| Price to sales ratio | 32.67 | 41.01 | 34.47 | 27.11 | 24.54 | |
| POCF ratio | 127.03 | 673.51 | 269.68 | 151.11 | 182.21 | |
| PFCF ratio | 232.33 | 5.05K | -1.09K | 250.97 | 253.1 | |
| P/B Ratio | 7.91 | 7.44 | 4.81 | 3.84 | 3.86 | |
| PTB ratio | 7.91 | 7.44 | 4.81 | 3.84 | 3.86 | |
| EV to sales | 30.79 | 38.41 | 32.38 | 25.2 | 22.59 | |
| Enterprise value over EBITDA | 145.46 | 244.52 | 195.02 | 171.45 | 338.11 | |
| EV to operating cash flow | 119.74 | 630.73 | 253.3 | 140.45 | 167.69 | |
| EV to free cash flow | 219 | 4.73K | -1.02K | 233.27 | 232.94 | |
| Earnings yield | 0.01 | 0 | 0 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | -0.02 | 0.01 | -0.02 | |
| Debt to assets | 0 | 0 | -0.01 | 0.01 | -0.02 | |
| Net debt to EBITDA | -8.86 | -16.58 | -12.61 | -13.01 | -29.27 | |
| Current ratio | 5.03 | 4.31 | 4.45 | 4.42 | 3.63 | |
| Interest coverage | 1 | 34.25 | 4.59K | 0 | 0 | |
| Income quality | 1 | 1 | 1 | 1.3 | 1.26 | |
| Dividend Yield | 0 | 0.01 | 0 | 0.01 | 0 | |
| Payout ratio | 0.11 | 8.83 | 0 | 1.05 | 0 | |
| Sales general and administrative to revenue | 0.12 | -0.06 | 0.09 | -0.03 | 0.19 | |
| Research and developement to revenue | 0.05 | 0.04 | 0.07 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.16 | 0.17 | 0.16 | |
| Capex to operating cash flow | -0.45 | -0.87 | -1.25 | -0.4 | -0.28 | |
| Capex to revenue | -0.12 | -0.05 | -0.16 | -0.07 | -0.04 | |
| Capex to depreciation | -3.75 | -1.29 | -1.95 | -0.89 | 0.26 | |
| Stock based compensation to revenue | -0.04 | 0.07 | 0 | 0.02 | -0.02 | |
| Graham number | 16.72 | 7.07 | 9.15 | 9.68 | 8.88 | |
| ROIC | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Return on tangible assets | 0.06 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Graham Net | 6.88 | 6.96 | 4.5 | 4.45 | 4.37 | |
| Working capital | 911.14M | 870.7M | 640.76M | 644.32M | 635.35M | |
| Tangible asset value | 1.49B | 1.51B | 1.34B | 1.33B | 1.31B | |
| Net current asset value | 901.57M | 858.29M | 628.68M | 623.65M | 615.11M | |
| Invested capital | 0 | 0 | -0.02 | 0.01 | -0.02 | |
| Average receivables | 131.1M | 259.68M | 240.74M | 230.1M | 248.11M | |
| Average payables | 126.94M | 127.77M | 118.56M | 89.39M | 83.66M | |
| Average inventory | 146.13M | 120.67M | 122.15M | 120.35M | 117.79M | |
| Days sales outstanding | 61.99 | 80.07 | 89.26 | 91.5 | 92.08 | |
| Days payables outstanding | 41.38 | 68.57 | 54.67 | 49.15 | 40.62 | |
| Days of inventory on hand | 46.14 | 56.2 | 75.33 | 64.62 | 61.52 | |
| Receivables turnover | 1.45 | 1.12 | 1.01 | 0.98 | 0.98 | |
| Payables turnover | 2.17 | 1.31 | 1.65 | 1.83 | 2.22 | |
| Inventory turnover | 1.95 | 1.6 | 1.19 | 1.39 | 1.46 | |
| ROE | 0.06 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex per share | -0.4 | -0.14 | -0.32 | -0.15 | -0.09 |
605369.SS Frequently Asked Questions
What is Zhejiang Gongdong Medical Technology Co.,Ltd. stock symbol ?
Zhejiang Gongdong Medical Technology Co.,Ltd. is a CN stock and trading under the symbol 605369.SS
What is Zhejiang Gongdong Medical Technology Co.,Ltd. stock quote today ?
Zhejiang Gongdong Medical Technology Co.,Ltd. stock price is $43.13 today.
Is Zhejiang Gongdong Medical Technology Co.,Ltd. stock public?
Yes, Zhejiang Gongdong Medical Technology Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 555.81K
- Market Capitalization 5.47B
- Employee 1.78K
- CEO Mr. Weifeng Zhong
- Headquarters Taizhou,CN
- IPO Date 2020-09-16
-
Website
https://www.chinagongdong.com 
Zhejiang Gongdong Medical Technology Co.,Ltd. develops, produces, and sells medical devices and medical testing supplies in China. Its products include lab consumables, vacuum blood collection systems, specimen collection systems, medical nursing wares, medicine package wares, nd mold customization products. Zhejiang Gongdong Medical Technology Co.,Ltd.was founded in 1985 and is based in Taizhou, China.
